SmartBio Analytics supports pharmaceutical companies, biotechnology organisations, CROs and academic research groups with fast, reliable and GLP-compliant bioanalytical services throughout every stage of drug development and scientific research.
Each client and every stage of development has different priorities. In early discovery, adaptability and flexibility are key to supporting evolving research needs. In advanced clinical phases or regulatory studies, traceability, speed, and compliance become paramount.
This is where SmartBio Analytics excels: our combination of scientific expertise, operational agility, and regulatory rigor makes us the perfect partner for any type of company, at any stage of the drug development process.
From new chemical entities to generics, we deliver robust, GLP-compliant data to meet global regulatory requirements, with method development in 1–2 weeks, validation in 4–6 weeks, and analysis results in ≤ 5 days.
Flexible, cost-efficient bioanalytical solutions for innovative therapies, including biomarker quantification. Experienced in multi-partner collaborations and committed to accelerating development while optimizing resources.
We act as your laboratory extension, providing seamless bioanalytical capabilities with full logistical reliability, clear communication, and regulatory compliance — backed by founders with years of CRO experience.
Academic R&D
From innovative and generic small molecules to peptides, oligonucleotides, lipids, and proteins
Methods in 1–2 weeks, validations in 4–6 weeks, analysis results in ≤ 5 days
Full traceability and adherence to QA & Certifications standards
Tailored workflows that match the pace and requirements of each development stage
Meet our scientists on the Team page
Whether you are accelerating discovery, preparing for clinical trials, or conducting regulatory bioequivalence studies, SmartBio Analytics delivers the data you need, on time, every time.
